Medicenna Therapeutics Corp. announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. The highlights of the data set will be presented by: Dr. Steven Brem, M.D., Medical Director, Centre for Precision Surgery, Abramson Cancer Center, Perelman School of Medicenna, University Of Pennsylvania.

Details for the SNO 2023 Poster Presentation: Title: Survival Outcomes in Recurrent Glioblastoma (rGBM) Patients Treated with a Single Intra-tumoral Administration of Bizaxofusp, an IL-4R-targeting Toxin, in a Phase IIb Trial. Presenter: Dr. Steven B Rem, M.D., University of Pennsylvania. Abstract number: CTNI-52 Session: Clinical Trials: Non-immunologic Presentation date and time: November 17, 2023; 7:30 p.m. PT.

About Bizaxofusp: Bizaxofusp is Medicenna's IL-4 Empowered Superkine that has been studied in 5 clinical trials in over 130 patients, including a Phase 2b trial in patients with recurrent glioblastoma (r GBM), the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage BiSKITs??

program (Bifunctional SuperKine ImmunoTherapies) and T-MASK (Targeted Metalloprotease Activated SuperKines) programs are in pre-clinical development designed to enhance the ability of Superkines to treat immunologically " cold" tumors.